Dittadi R, Brazzale A, Pappagallo G, Salbe C, Nascimben O, Rosabian A, Gion M
Center for the Study of Biological Markers of Malignancy, Regional General Hospital, Venice, Italy.
Anticancer Res. 1997 Mar-Apr;17(2B):1245-7.
ErbB2/neu protein (p185) expression was evaluated by ELISA in 115 breast cancer specimens. Distribution was subdivided in quartiles and showed a distinct behaviour in comparison with both clinico-biological parameters and clinical outcome. In particular, intermediate concentration groups showed a significantly better disease-free survival than the low and high concentration groups (p = 0.02). We classified the patients as "low risk" (64 samples with p185 concentrations between 2150 and 30000 U/mg of proteins) and "high risk" on the basis of the results of the multivariate analysis. The p185 grouped as described showed a significant relationship with the disease free survival in multivariate analysis. Although the data must be considered as preliminary, they suggest the possibility of identifying more appropriately the high risk patients through the biochemical determination of p185.
通过酶联免疫吸附测定（ELISA）对115份乳腺癌标本中的ErbB2/neu蛋白（p185）表达进行了评估。分布情况被细分为四分位数，并且与临床生物学参数和临床结果相比显示出不同的表现。特别是，中等浓度组的无病生存率明显优于低浓度组和高浓度组（p = 0.02）。根据多变量分析结果，我们将患者分为“低风险”（64份样本，p185浓度在2150至30000 U/mg蛋白质之间）和“高风险”。如上述分组的p185在多变量分析中与无病生存率存在显著关系。尽管这些数据必须被视为初步数据，但它们表明通过p185的生化测定更准确地识别高风险患者的可能性。
